Table 4. Changes in skin texture evaluated by participants and clinicians in numeric scale.
| Variable | iBTXA | Normal saline (N/S) | iBTXA vs N/S | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 0 | 1 | 2 | 3 | 4 | p-value* | 0 | 1 | 2 | 3 | 4 | p-value* | p-value | ||
| Improvement of skin texture evaluated by participants | ||||||||||||||
| Week 2 | 6 (40.0) | 3 (20.0) | 4 (26.7) | 2 (13.3) | 0 (0.0) | 0.02 | 11 (73.3) | 2 (13.3) | 2 (13.3) | 0 (0.0) | 0 (0.0) | 0.50 | 0.032 | |
| Week 4 | 2 (13.3) | 2 (13.3) | 6 (40.0) | 4 (26.7) | 1 (6.7) | <0.01 | 10 (66.7) | 4 (26.7) | 1 (6.7) | 0 (0.0) | 0 (0.0) | 0.25 | <0.01 | |
| Week 8 | 5 (33.3) | 3 (20.0) | 3 (20.0) | 4 (26.7) | 0 (0.0) | <0.01 | 10 (66.7) | 4 (26.7) | 1 (6.7) | 0 (0.0) | 0 (0.0) | 0.25 | 0.06 | |
| Week 12 | 9 (60.0) | 2 (13.3) | 3 (20.0) | 1 (6.7) | 0 (0.0) | 0.13 | 13 (86.7) | 2 (13.3) | 0 (0.0) | 0 (0.0) | 0 (0.0) | >0.99 | 0.23 | |
| Improvement of skin texture evaluated by clinicians | ||||||||||||||
| Week 2 | 1 (6.7) | 2 (13.3) | 10 (66.7) | 2 (13.3) | 0 (0.0) | <0.01 | 14 (93.3) | 1 (6.7) | 0 (0.0) | 0 (0.0) | 0 (0.0) | >0.99 | <0.01 | |
| Week 4 | 1 (6.7) | 1 (6.7) | 10 (66.7) | 3 (20.0) | 0 (0.0) | <0.01 | 14 (93.3) | 1 (6.7) | 0 (0.0) | 0 (0.0) | 0 (0.0) | >0.99 | <0.01 | |
| Week 8 | 2 (13.3) | 7 (46.7) | 3 (20.0) | 3 (20.0) | 0 (0.0) | <0.01 | 15 (100.0) | 0 (0.00) | 0 (0.0) | 0 (0.0) | 0 (0.0) | - | - | |
| Week 12 | 8 (53.3) | 5 (33.3) | 2 (13.3) | 0 (0.0) | 0 (0.0) | 0.06 | 15 (100.0) | 0 (0.00) | 0 (0.0) | 0 (0.0) | 0 (0.0) | - | - | |
Values are presented as number (%) unless otherwise indicated. iBTXA: incobotulinum toxin A. *Compared to week 0.